RS62732B1 - Inhibitori creb vezujućeg proteina (cbp) - Google Patents
Inhibitori creb vezujućeg proteina (cbp)Info
- Publication number
- RS62732B1 RS62732B1 RS20211321A RSP20211321A RS62732B1 RS 62732 B1 RS62732 B1 RS 62732B1 RS 20211321 A RS20211321 A RS 20211321A RS P20211321 A RSP20211321 A RS P20211321A RS 62732 B1 RS62732 B1 RS 62732B1
- Authority
- RS
- Serbia
- Prior art keywords
- c6alkyl
- methyl
- compound
- aryl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692593P | 2018-06-29 | 2018-06-29 | |
| PCT/US2018/051214 WO2019055869A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| PCT/US2018/051235 WO2019055877A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| US201962819490P | 2019-03-15 | 2019-03-15 | |
| US16/457,596 US10870648B2 (en) | 2018-06-29 | 2019-06-28 | Inhibiting CREB binding protein (CBP) |
| PCT/US2019/039936 WO2020006483A1 (en) | 2018-06-29 | 2019-06-28 | Inhibiting creb binding protein (cbp) |
| EP19183741.8A EP3587418B1 (en) | 2018-06-29 | 2019-07-01 | Inhibitors of creb binding protein (cbp) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS62732B1 true RS62732B1 (sr) | 2022-01-31 |
Family
ID=68987627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20211321A RS62732B1 (sr) | 2018-06-29 | 2019-07-01 | Inhibitori creb vezujućeg proteina (cbp) |
Country Status (26)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023013508A (es) * | 2018-06-29 | 2023-12-13 | Forma Therapeutics Inc | Inhibicion de la proteina de union a creb (cbp). |
| WO2020190792A1 (en) * | 2019-03-15 | 2020-09-24 | Forma Therapeutics, Inc. | Compositions and methods for treating androgen receptor positive forms of cancer |
| EP3937940A4 (en) | 2019-03-15 | 2022-12-21 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (creb) |
| MX2022016498A (es) | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Una combinacion de un inhibidor de cbp/p300 bromodominio y un inhibidor de kras. |
| IL299438A (en) | 2020-06-25 | 2023-02-01 | Tolremo Therapeutics Ag | A combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for use in the treatment of EGFR-mutated NSCLC |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404207A (en) | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
| US5138089A (en) * | 1986-06-27 | 1992-08-11 | The Procter & Gamble Company | Chromophores, sunscreen compositions and methods for preventing sunburn |
| WO1995020589A1 (en) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| AU2002218190A1 (en) | 2000-11-20 | 2002-05-27 | Merck Patent G.M.B.H | Chiral photoisomerizable compounds |
| CA2463136A1 (en) | 2001-10-17 | 2003-04-24 | Raymond Andersen | Ship 1 modulators |
| AU2002349477A1 (en) | 2001-11-26 | 2003-06-10 | Takeda Chemical Industries, Ltd. | Bicyclic derivative, process for producing the same, and use |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| TWI322012B (en) | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
| IN2003CH00929A (cg-RX-API-DMAC7.html) | 2003-11-13 | 2008-10-06 | ||
| WO2005066162A1 (en) | 2003-12-23 | 2005-07-21 | Human Biomolecular Research Institute | Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer |
| WO2005099688A2 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| WO2007120339A1 (en) | 2005-12-19 | 2007-10-25 | Genentech, Inc. | Pyrimidine kinase inhibitors |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| CA2652235A1 (en) | 2006-05-09 | 2007-11-22 | Hemaquest Pharmaceuticals, Inc. | Methods for treating blood disorders |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| CA2574531C (en) | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| WO2008157680A2 (en) | 2007-06-21 | 2008-12-24 | The Wistar Institute | Methods and compositions for modulating p300/cbp activity |
| ATE539063T1 (de) | 2007-06-26 | 2012-01-15 | Sanofi Sa | Regioselektive, kupferkatalysierte synthese von benzimidazolen und azabenzimidazolen |
| WO2009001817A1 (ja) | 2007-06-27 | 2008-12-31 | Taisho Pharmaceutical Co., Ltd. | １１β－ＨＳＤ１阻害活性を有する化合物 |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| US8592465B2 (en) | 2008-06-16 | 2013-11-26 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| WO2010110380A1 (ja) * | 2009-03-27 | 2010-09-30 | 興和株式会社 | 縮合ピペリジン化合物及びこれを含有する医薬 |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| JP5657642B2 (ja) | 2009-04-15 | 2015-01-21 | ジェイダブリュ ファーマセウティカル コーポレーション | リバースターン類似体の新規な化合物およびその製造方法と用途 |
| WO2010138487A1 (en) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE |
| WO2010138490A1 (en) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture |
| WO2011085039A2 (en) | 2010-01-05 | 2011-07-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| EP2542081A4 (en) | 2010-03-01 | 2013-07-31 | Gtx Inc | COMPOSITIONS FOR CANCER TREATMENT |
| CA2800618C (en) * | 2010-05-26 | 2018-08-28 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US8906943B2 (en) | 2010-08-05 | 2014-12-09 | John R. Cashman | Synthetic compounds and methods to decrease nicotine self-administration |
| JP2014503528A (ja) | 2010-12-14 | 2014-02-13 | エレクトロプホレトイクス リミテッド | カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用 |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| US9295754B2 (en) | 2011-02-24 | 2016-03-29 | Emory University | Noggin inhibitory compositions for ossification and methods related thereto |
| TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| WO2013148114A1 (en) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| US9211333B2 (en) | 2012-06-05 | 2015-12-15 | Hong Kong Baptist University | Anti-cancer agents synthesized based on miliusane compounds |
| IN2015DN02008A (cg-RX-API-DMAC7.html) | 2012-09-21 | 2015-08-14 | Advinus Therapeutics Ltd | |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| WO2015004534A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| HRP20200854T1 (hr) | 2013-06-21 | 2020-08-21 | Zenith Epigenetics Ltd. | Novi biciklički inhibitori bromodomene |
| EP3024327B1 (en) | 2013-07-25 | 2019-09-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| DE102013215912B3 (de) | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| TW201605859A (zh) | 2013-11-14 | 2016-02-16 | 必治妥美雅史谷比公司 | 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌 |
| WO2015074081A1 (en) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Benzopiperazine compositions as bet bromodomain inhibitors |
| LT3071203T (lt) | 2013-11-18 | 2021-05-25 | Forma Therapeutics, Inc. | Tetrahidrochinolino kompozicijos kaip bet bromodomeno inhibitoriai |
| JP2017529358A (ja) | 2014-09-19 | 2017-10-05 | ジェネンテック， インコーポレイテッド | がんの処置のためのｃｂｐ／ｅｐ３００阻害剤およびｂｅｔ阻害剤の使用 |
| JP6771464B2 (ja) * | 2014-11-27 | 2020-10-21 | ジェネンテック， インコーポレイテッド | Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物 |
| EP3242878B1 (en) | 2015-01-08 | 2020-10-14 | Impetis Biosciences Ltd. | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| US11883381B2 (en) | 2016-05-12 | 2024-01-30 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| CN115028617A (zh) | 2016-05-24 | 2022-09-09 | 基因泰克公司 | Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途 |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| JP2020516672A (ja) * | 2017-04-18 | 2020-06-11 | セルジーン クオンティセル リサーチ，インク． | 治療用化合物 |
| CA3075880A1 (en) * | 2017-09-15 | 2019-03-21 | Forma Therapeutics, Inc. | Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors |
| MX2023013508A (es) * | 2018-06-29 | 2023-12-13 | Forma Therapeutics Inc | Inhibicion de la proteina de union a creb (cbp). |
-
2019
- 2019-06-28 MX MX2023013508A patent/MX2023013508A/es unknown
- 2019-06-28 CA CA3105099A patent/CA3105099A1/en active Pending
- 2019-06-28 WO PCT/US2019/039936 patent/WO2020006483A1/en not_active Ceased
- 2019-06-28 SG SG11202012767UA patent/SG11202012767UA/en unknown
- 2019-06-28 BR BR112020026783-0A patent/BR112020026783A2/pt unknown
- 2019-06-28 CN CN201980050022.XA patent/CN112513038B/zh active Active
- 2019-06-28 IL IL321337A patent/IL321337A/en unknown
- 2019-06-28 KR KR1020257014745A patent/KR20250067962A/ko active Pending
- 2019-06-28 CN CN202211658329.8A patent/CN116178369A/zh active Pending
- 2019-06-28 AU AU2019295790A patent/AU2019295790B2/en active Active
- 2019-06-28 MX MX2020014303A patent/MX2020014303A/es unknown
- 2019-06-28 US US16/457,596 patent/US10870648B2/en active Active
- 2019-06-28 IL IL279734A patent/IL279734B2/en unknown
- 2019-06-28 KR KR1020217002866A patent/KR102805503B1/ko active Active
- 2019-07-01 HU HUE19183741A patent/HUE056885T2/hu unknown
- 2019-07-01 MA MA50675A patent/MA50675B1/fr unknown
- 2019-07-01 SM SM20210636T patent/SMT202100636T1/it unknown
- 2019-07-01 LT LTEP19183741.8T patent/LT3587418T/lt unknown
- 2019-07-01 PT PT191837418T patent/PT3587418T/pt unknown
- 2019-07-01 JP JP2019123100A patent/JP6781806B2/ja active Active
- 2019-07-01 EP EP21193994.7A patent/EP3998266A1/en active Pending
- 2019-07-01 SI SI201930136T patent/SI3587418T1/sl unknown
- 2019-07-01 DK DK19183741.8T patent/DK3587418T3/da active
- 2019-07-01 HR HRP20211698TT patent/HRP20211698T1/hr unknown
- 2019-07-01 RS RS20211321A patent/RS62732B1/sr unknown
- 2019-07-01 ES ES19183741T patent/ES2900105T3/es active Active
- 2019-07-01 PL PL19183741T patent/PL3587418T3/pl unknown
-
2020
- 2020-05-28 JP JP2020093126A patent/JP7017801B2/ja active Active
- 2020-06-08 US US16/946,159 patent/US11254674B2/en active Active
- 2020-12-17 JP JP2020209005A patent/JP2021042255A/ja not_active Withdrawn
- 2020-12-28 SA SA520420909A patent/SA520420909B1/ar unknown
-
2021
- 2021-01-25 ZA ZA2021/00509A patent/ZA202100509B/en unknown
- 2021-11-22 CY CY20211101010T patent/CY1124762T1/el unknown
-
2022
- 2022-02-10 US US17/669,112 patent/US12378242B2/en active Active
- 2022-09-23 ZA ZA2022/10560A patent/ZA202210560B/en unknown
-
2023
- 2023-09-05 AU AU2023226653A patent/AU2023226653B2/en active Active
-
2024
- 2024-06-09 IL IL313466A patent/IL313466B2/en unknown
-
2025
- 2025-03-21 JP JP2025046918A patent/JP2025094157A/ja active Pending
- 2025-07-29 AU AU2025210762A patent/AU2025210762A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS62732B1 (sr) | Inhibitori creb vezujućeg proteina (cbp) | |
| TWI795440B (zh) | 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物 | |
| AU2025200607A1 (en) | Inhibting cyclic amp-responsive element-binding protein (creb) | |
| EP3587418B1 (en) | Inhibitors of creb binding protein (cbp) | |
| RU2803290C2 (ru) | Ингибирование creb-связывающего белка (cbp) | |
| HK40074924A (en) | Inhibiting creb binding protein (cbp) | |
| HK40018316A (en) | Inhibitors of creb binding protein (cbp) | |
| HK40018316B (en) | Inhibitors of creb binding protein (cbp) | |
| MD3587418T2 (ro) | Inhibitori ai proteinei de legare CREB (CBP) | |
| BR122025003836A2 (pt) | Composto e composição farmacêutica | |
| EA042920B1 (ru) | Ингибирование creb-связывающего белка (cbp) | |
| EA046876B1 (ru) | Ингибирование creb-связывающего белка (cbp) | |
| EP3937940A1 (en) | Inhibiting cyclic amp-responsive element-binding protein (creb) |